Literature DB >> 17170544

Increasing AV fistulae and decreasing dialysis catheters: two aspects of improving patient outcomes.

Jeffrey J Sands1.   

Abstract

Maximizing arteriovenous (AV) fistula prevalence and minimizing catheter use have become the dominant issues in hemodialysis vascular access management and offer the promise of improved patient outcomes with decreased overall expenditures. Recent efforts have increased AV fistula prevalence in the US to 42.9% with regional rates as high as 59.5% and with complementary declines in AV grafts. This should decrease access procedures but may not fully realize the potential reductions in mortality and cost possible if combined with catheter reduction. Successful catheter reduction requires similar approaches to those utilized in the Fistula First Program. Educating patients, the use of clearly defined protocols and updating payment systems to include chronic kidney disease care are crucial to continued progress. Expansion of the Fistula First Program to include a focus on decreasing catheter prevalence and complications should be considered as a requirement in the push toward the breakthrough targets of 66% AV fistula prevalence. Copyright (c) 2007 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2006        PMID: 17170544     DOI: 10.1159/000096404

Source DB:  PubMed          Journal:  Blood Purif        ISSN: 0253-5068            Impact factor:   2.614


  2 in total

1.  Change in vascular access and hospitalization risk in long-term hemodialysis patients.

Authors:  Eduardo Lacson; Weiling Wang; J Michael Lazarus; Raymond M Hakim
Journal:  Clin J Am Soc Nephrol       Date:  2010-09-30       Impact factor: 8.237

2.  Consistent aspirin use associated with improved arteriovenous fistula survival among incident hemodialysis patients in the dialysis outcomes and practice patterns study.

Authors:  Takeshi Hasegawa; Stacey J Elder; Jennifer L Bragg-Gresham; Ronald L Pisoni; Shin Yamazaki; Tadao Akizawa; Michel Jadoul; Rayner C Hugh; Friedrich K Port; Shunichi Fukuhara
Journal:  Clin J Am Soc Nephrol       Date:  2008-07-02       Impact factor: 8.237

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.